Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Kimberly M. Lau"'
Publikováno v:
Journal of Oncology Pharmacy Practice. 27:821-826
Introduction Blinatumomab is a CD19/CD3 bispecific T-cell engager (BiTE) antibody that simultaneously binds CD19 on the surface of B-cells and CD3 on the surface of T-cells, resulting in tumor cell lysis. It is approved for the treatment of patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ebc84c849643c98a465a51f216d05204
https://doi.org/10.1177/1078155220934853
https://doi.org/10.1177/1078155220934853
Publikováno v:
Journal of Oncology Pharmacy Practice. 26:1390-1396
Introduction Head and neck cancers (HNC) are a complex and heterogeneous group of cancers, often necessitating a multidisciplinary approach across the care continuum. Oncology pharmacists are uniquely qualified to play a vital role on a multidiscipli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d17c942b938d661dc7a9bf738001c50f
https://doi.org/10.1177/1078155219897129
https://doi.org/10.1177/1078155219897129
Autor:
Sandy On, Carolyn G. Rath, Michelle Lan, Bobby Wu, Kimberly M. Lau, Edna Cheung, William Alegria, Rebecca Young, Marisela Tan, Carrie Kim, Jennifer Phun, Nimish Patel, Gabriel Mannis, Aaron C. Logan, Vanessa Kennedy, Aaron Goodman, Randy A. Taplitz, Patricia A. Young, Raymond Wen, Ila M. Saunders
Publikováno v:
British journal of haematologyREFERENCES. 197(1)
We investigated the incidence of invasive fungal infections (IFIs) and other infectious complications in patients receiving venetoclax and hypomethylating agent therapy for acute myeloid leukaemia (AML). This retrospective, multicentre cohort study i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42a67d10a764accfe0d58d9ee3e8fb74
https://pubmed.ncbi.nlm.nih.gov/35174480
https://pubmed.ncbi.nlm.nih.gov/35174480
Publikováno v:
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 26(1)
Pegaspargase, a long acting formulation of L-asparaginase, is an asparagine specific enzyme that selectively kills leukemic cells by depleting plasma asparagine. Pegaspargase is FDA approved for the first-line treatment of adult acute lymphoblastic l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90a0b051dcd04ec7dde3423a99a80ba0
https://pubmed.ncbi.nlm.nih.gov/30823860
https://pubmed.ncbi.nlm.nih.gov/30823860
Autor:
Christian A Smith, Kimberly M Lau, Zohra Rahmani, Sascha E Dho, Greg Brothers, Ye Min She, Donna M Berry, Eric Bonneil, Pierre Thibault, François Schweisguth, Roland Le Borgne, C Jane McGlade
In Drosophila, the partition defective (Par) complex containing Par3, Par6 and atypical protein kinase C (aPKC) directs the polarized distribution and unequal segregation of the cell fate determinant Numb during asymmetric cell divisions. Unequal seg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19f5dbaf96e54f97b4be67e8ef3ca988
https://europepmc.org/articles/PMC1783459/
https://europepmc.org/articles/PMC1783459/
